Shares in Abionyx Pharma rose around 15% in early trading in Paris.
Abionyx Pharma has hailed the success of a phase 2a clinical trial designed to resurrect a cholesterol drug that first flamed out almost a decade ago. But with the French biotech yet to share numbers from the study, it is unclear whether the mimic of HDL cholesterol has a future in the treatment of septic patients.
A phase 2a clinical trial in septic patients at high risk of developing acute kidney injury is an early test of the pivot. Abionyx said CER-001 cleared the test—but the data-devoid statement published by the biotech makes it impossible for outsiders to fully gauge how the candidate performed in the trial.
According to Abionyx, the study met its primary objective. The EU clinical trial registry lists the co-primary endpoints of the trial as determination of the optimal dose and the onset and severity of acute kidney injury. The study’s lead investigator noted the “trend observed in reducing renal damage” in a statement to disclose the results.
Abionyx also noted “positive results” on secondary endpoints. The biotech reported a “significant effect” on endotoxin removal and “consequent reduction in the inflammatory cascade,” plus a “significant protective effect … on endothelial functionality” and trends toward fewer ICU days, lower requirement for organ support and improved 30-day survival.
Safety was reportedly in line with the results of a COVID-19 trial that read out last year. Abionyx is yet to say when it will present the full data set but did outline plans to discuss the results with regulators, first in Europe and later in the U.S., “to design an appropriate clinical and regulatory development strategy for this disease state.”
Abionyx will need to secure funding for further development. The biotech ended September with just 3.8 million euros ($4.1 million) to its name. Shares in Abionyx rose around 15% in early trading in Paris, climbing to 2.22 euros per share.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.